share_log

加科思-B:自願公告 SHP2抑制劑JAB-3312與KRAS G12C抑制劑戈來雷塞聯用註冊性三期臨床研究獲國家藥品監督管理局藥品審評中心(CDE)批准

JACOBIO-B: VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL PHASE III CLINICAL TRIAL OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB APPROVED BY THE CENTER FOR DRUG EVALUATION (CDE) OF THE NMPA

香港交易所 ·  Feb 18 06:50
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more